Acute kidney injury in villous cancer patients treated with vancomycin and tazobactam/piperacillin

Acute kidney injury in villous cancer patients treated with vancomycin and tazobactam/piperacillin

Bibliographic Details
Main Authors:	Kaori Nakatani, Kenji Momo, Takashi Mimura, Eri Yoshiizumi, Tadanori Sasaki
Format:	Article
Language:	English
Published:	Wiley 2022-08-01
Series:	Clinical Case Reports
Subjects:	acute kidney injury drug–drug interaction tazobactam/piperacillin vancomycin
Online Access:	https://doi.org/10.1002/ccr3.6081

Similar Items

Comparison of risk of acute kidney injury between patients receiving the combination of teicoplanin and piperacillin/tazobactam versus vancomycin and piperacillin/tazobactam
by: Chi-Hao Shao, et al.
Published: (2022-01-01)

Evaluation of Strategies for Reducing Vancomycin-Piperacillin/Tazobactam Incompatibility
by: Anthony Martin Mena, et al.
Published: (2023-08-01)

Lowered Risk of Nephrotoxicity through Intervention against the Combined Use of Vancomycin and Tazobactam/Piperacillin: A Retrospective Cohort Study
by: Kazutaka Oda, et al.
Published: (2021-09-01)

Piperacillin–Tazobactam Plus Vancomycin-Associated Acute Kidney Injury in Adults: Can Teicoplanin or Other Antipseudomonal Beta-Lactams Be Remedies?
by: Abdullah Tarık Aslan, et al.
Published: (2022-08-01)

Acute kidney injury associated with concomitant use of vancomycin with piperacillin-tazobactam: a focused review and meta-analysis
by: Hatice Duygu Bas, et al.
Published: (2016-06-01)

Comparative Risk of Acute Kidney Injury Following Concurrent Administration of Vancomycin with Piperacillin/Tazobactam or Meropenem: A Systematic Review and Meta-Analysis of Observational Studies
by: Abdulmajeed M. Alshehri, et al.
Published: (2022-04-01)

Mechanisms of Piperacillin/Tazobactam Nephrotoxicity: Piperacillin/Tazobactam-Induced Direct Tubular Damage in Mice
by: Jihyun Yang, et al.
Published: (2023-06-01)

Assessment of knowledge, attitude, and practices of acute kidney injury incidence with co-administration of piperacillin/tazobactam and vancomycin among healthcare workers: A cross-sectional study
by: Haytham A. Wali, et al.
Published: (2023-06-01)

Acute kidney injury associated with piperacillin-tazobactam versus other antibiotics combined with vancomycin in critically ill patients: A retrospective cohort study
by: Masaad S. Almutairi, et al.
Published: (2023-12-01)

Rapid onset severe thrombocytopenia following reexposure to piperacillin-tazobactam: report of two cases and review of the literature
by: Musa Alzahrani, et al.
Published: (2018-08-01)

Piperacillin/Tazobactam-Induced Neutropenia: A Case Report
by: Hayati DEMİRASLAN, et al.
Published: (2012-03-01)

Evaluation of Piperacillin/Tazobactam Use and Resistance Pattern in a Teaching Hospital, Northwest Iran
by: Afshin Shiva, et al.
Published: (2022-06-01)

Comparison of Cefepime with Piperacillin/Tazobactam Treatment in Patients with Hospital-Acquired Pneumonia
by: Bo-Guen Kim, et al.
Published: (2023-05-01)

Is Piperacillin-Tazobactam an Appropriate Empirical Agent for Hospital-Acquired Sepsis and Community-Acquired Septic Shock of Unknown Origin in Australia?
by: Alice Gage-Brown, et al.
Published: (2022-05-01)

Impact of extended-infusion piperacillin-tazobactam in a Canadian community hospital
by: April J. Chan, et al.
Published: (2023-03-01)

Comparison of Piperacillin and Tazobactam Pharmacokinetics in Critically Ill Patients with Trauma or with Burn
by: Daniel J. Selig, et al.
Published: (2022-05-01)

Simple HPLC-UV Method for Piperacillin/Tazobactam Assay in Human Plasma
by: Khaled Abdelkawy, et al.
Published: (2023-02-01)

Galactomannan detection from piperacillin-tazobactam brands available in the Brazilian market
by: Melissa Orzechowski Xavier, et al.

A Case of DRESS Syndrome Associated with Piperacillin-Tazobactam Treatment and Literature Review
by: Seven ULUDOKUMACI, et al.
Published: (2012-12-01)

Piperacillin/tazobactam in modern clinical practice
by: Igor Bereznyakov
Published: (2022-05-01)

The effect of meropenem versus piperacillin-tazobactam in critically ill patients with sepsis and septic shock
by: Yang Sun, et al.
Published: (2023-06-01)

Similar Piperacillin/Tazobactam Target Attainment in Obese versus Nonobese Patients despite Differences in Interstitial Tissue Fluid Pharmacokinetics
by: David Busse, et al.
Published: (2021-08-01)

Pathogen-based target attainment of optimized continuous infusion dosing regimens of piperacillin-tazobactam and meropenem in surgical ICU patients: a prospective single center observational study
by: Thomas De Corte, et al.
Published: (2023-04-01)

Incidence and Determinants of Piperacillin/Tazobactam-Associated Hypokalemia: A Retrospective Study
by: Heenam Seo, et al.
Published: (2022-08-01)

Higher incidence of acute kidney injury in patients treated with piperacillin/tazobactam than in patients treated with cefepime: a single-center retrospective cohort study
by: Shota Kadomura, et al.
Published: (2019-06-01)

Susceptive piperacillin-tazobactam-induced Evans syndrome after radical resection of esophageal cancer: A rare case report
by: Yan Li, et al.
Published: (2023-12-01)

Synthesis and evaluation of polymeric micelle containing piperacillin/tazobactam for enhanced antibacterial activity
by: Milani Morteza, et al.
Published: (2019-01-01)

Risk factors of nosocomial infections caused by piperacillin-tazobactam resistant Pseudomonas aeruginosa
by: Đorđević Zorana, et al.
Published: (2013-01-01)

Evaluation of Piperacillin/Sulbactam, Piperacillin/Tazobactam and Cefoperazone/Sulbactam Dosages in Gram-Negative Bacterial Bloodstream Infections by Monte Carlo Simulation
by: Xueting Wang, et al.
Published: (2023-02-01)

Drug-induced hypersensitivity syndrome related to piperacillin-tazobactam: a case report and review of the literature
by: Ya Shen, et al.
Published: (2024-03-01)

Piperacillin/Tazobactam Co-Delivery by Micellar Ionic Conjugate Systems Carrying Pharmaceutical Anions and Encapsulated Drug
by: Katarzyna Niesyto, et al.
Published: (2024-01-01)

Evaluating the Nephrotoxicity of Area-under-the-Curve-Based Dosing of Vancomycin with Concomitant Antipseudomonal Beta-Lactam Antibiotics: A Systematic Review and Meta-Analysis
by: Chia-Yu Chiu, et al.
Published: (2023-03-01)

Superinfection rate among the patients treated with carbapenem versus piperacillin/tazobactam: Retrospective observational study
by: Hessa Al Muqati, et al.
Published: (2021-03-01)

A meta-analysis of piperacillin/tazobactam versus cefepime treatment in cancer patients with febrile neutropenia
by: Zhang Weidong, et al.
Published: (2016-12-01)

Diminished Susceptibility to Cefoperazone/Sulbactam and Piperacillin/Tazobactam in Enterobacteriaceae Due to Narrow-Spectrum β-Lactamases as Well as Omp Mutation
by: Yang Fengzhen, et al.
Published: (2022-06-01)

Piperacillin/Tazobactam in critically ill morbidly obese patients: A case series: The first One‐Centre experience with TDM
by: M. Mieresova, et al.
Published: (2023-03-01)

Design of an Experimental Study for the Simultaneous Determination of Cefepime, Piperacillin and Tazobactam Using Micellar Organic Solvent-Free HPLC
by: Hani M. Hafez, et al.
Published: (2022-08-01)

Comparable Effectiveness of Cefuroxime and Piperacillin-Tazobactam as Empirical Therapy for Methicillin-Susceptible Staphylococcus aureus Bacteremia
by: Robert Strengen Bigseth, et al.
Published: (2022-06-01)

FT-IR/ATR Solid Film Formation: Qualitative and Quantitative Analysis of a Piperacillin-Tazobactam Formulation
by: Ioanna Chrisikou, et al.
Published: (2020-12-01)

A case report of systemic muscle tremor and numbness induced by injection of piperacillin sodium and tazobactam sodium
by: Zhang Wei, Yan Huilan, Sui Xiaona, Song Shuangshuang
Published: (2022-08-01)